Image 3_Efficacy and safety of therapeutic exercise for primary dysmenorrhea: a systematic review and meta-analysis.jpeg by Yi Xiang (511856)

Table 1_Efficacy and safety of therapeutic exercise for primary dysmenorrhea: a systematic review and meta-analysis.docx by Yi Xiang (511856)

Image 5_Efficacy and safety of therapeutic exercise for primary dysmenorrhea: a systematic review and meta-analysis.jpeg by Yi Xiang (511856)

Image 2_Efficacy and safety of therapeutic exercise for primary dysmenorrhea: a systematic review and meta-analysis.jpeg by Yi Xiang (511856)

Image 4_Efficacy and safety of therapeutic exercise for primary dysmenorrhea: a systematic review and meta-analysis.jpeg by Yi Xiang (511856)

Image 1_Efficacy and safety of therapeutic exercise for primary dysmenorrhea: a systematic review and meta-analysis.jpeg by Yi Xiang (511856)

Image 6_Efficacy and safety of therapeutic exercise for primary dysmenorrhea: a systematic review and meta-analysis.jpeg by Yi Xiang (511856)

Supplementary Figure S2 from Early Prediction of Disease Progression in Small Cell Lung Cancer: Toward Model-Based Personalized Medicine in Oncology by Núria Buil-Bruna (14918931)

Figure S5 from Circadian Oscillations Persist in Cervical and Esophageal Cancer Cells Displaying Decreased Expression of Tumor-Suppressing Circadian Clock Genes by Pauline J. van der Watt (15068109)

Figure S1 from Circadian Oscillations Persist in Cervical and Esophageal Cancer Cells Displaying Decreased Expression of Tumor-Suppressing Circadian Clock Genes by Pauline J. van der Watt (15068109)

Supplementary tables from A Novel MYCN-Specific Antigene Oligonucleotide Deregulates Mitochondria and Inhibits Tumor Growth in MYCN-Amplified Neuroblastoma by Luca Montemurro (14937231)

Supplementary figure 2 from Secondary Tumors Arising in Patients Undergoing BRAF Inhibitor Therapy Exhibit Increased BRAF–CRAF Heterodimerization by Lise Boussemart (14915303)

Supplementary Figure 3 from Molecular Clusters and Tumor-Immune Drivers of IgM Monoclonal Gammopathies by Patrizia Mondello (15045002)

Figure 2 from Individualized Prediction of Drug Response and Rational Combination Therapy in NSCLC Using Artificial Intelligence–Enabled Studies of Acute Phosphoproteomic Changes by Elizabeth A. Coker (15024165)

Table_1_Decreases in Circulating Concentrations of Long-Chain Acylcarnitines and Free Fatty Acids During the Glucose Tolerance Test Represent Tissue-Specific Insulin Sensitivity.XL... by Elina Makarova (8131086)

“…The aim of this study was to measure free fatty acid (FFA) and acylcarnitine levels during the glucose tolerance test as indicators of tissue-specific insulin resistance.…”

FIGURE 3 from PARP Inhibitors Effectively Reduce MAPK Inhibitor Resistant Melanoma Cell Growth and Synergize with MAPK Inhibitors through a Synthetic Lethal Interaction <i>In Vitro... by Lisa Marie Fröhlich (16838353)

Supplementary Figures from A Metastatic Mouse Model Identifies Genes That Regulate Neuroblastoma Metastasis by Bo Kyung A. Seong (14926620)

FIGURE 5 from Discovery and Characterization of ZL-2201, a Potent, Highly Selective, and Orally Bioavailable Small-molecule DNA-PK Inhibitor by Shruti Lal (16805936)

Figure S3 from Inhibition of <i>MCL-1</i> and MEK Overcomes MEK Inhibitor Resistance in Triple-Negative and Inflammatory Breast Cancers by Mohd Mughees (15998547)

Figure S4 from Inhibition of <i>MCL-1</i> and MEK Overcomes MEK Inhibitor Resistance in Triple-Negative and Inflammatory Breast Cancers by Mohd Mughees (15998547)